Psoriasis patients with psoriasis Area and Severity Index (PASI) 90 response achieve greater health-related quality-of-life improvements than those with PASI 75-89 response: results from two phase 3 studies of secukinumab

被引:46
作者
Elewski, Boni E. [1 ]
Puig, Lluis [2 ]
Mordin, Margaret [3 ]
Gilloteau, Isabelle [4 ]
Sherif, Bintu [5 ]
Fox, Todd [4 ]
Gnanasakthy, Ari [5 ]
Papavassilis, Charis [4 ]
Strober, Bruce E. [6 ,7 ]
机构
[1] Univ Alabama Birmingham, Birmingham, AL USA
[2] Hosp Santa Creu & Sant Pau, Dept Dermatol, Barcelona, Spain
[3] RTI Hlth Solut, Ann Arbor, MI USA
[4] Novartis Pharma AG, Basel, Switzerland
[5] RTI Hlth Solut, Res Triangle Pk, NC USA
[6] Univ Connecticut, Hlth Ctr, Farmington, CT USA
[7] Prob Med Res, Waterloo, ON, Canada
关键词
Psoriasis; secukinumab; patient-reported outcome; DLQI; PASI; IGA; SEVERE PLAQUE PSORIASIS; BIOLOGICAL THERAPIES; CONTROLLED-TRIAL; DOUBLE-BLIND; MODERATE; EFFICACY; SAFETY; DLQI; USABILITY; OUTCOMES;
D O I
10.1080/09546634.2017.1294727
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background: The emergence of new biological therapies showing high and sustained level of Psoriasis Area and Severity Index (PASI) 90 response has provided the possibility of both greater skin clearance and increased quality of life (QOL). Objective: To evaluate the association of greater response in skin clearance with improvements in skinrelated QOL up to 52 weeks. Methods: Subjects achieving various levels of skin clearance (PASI 90-100 or PASI 75-89) and Dermatology Life Quality Index (DLQI) (0/1) response were compared using ERASURE and FIXTURE trial data. Similar analyses with IGA ratings of Clear or Almost Clear were performed. Results: Significantly more PASI 90-100 responders at week 12 had DLQI 0/1 response than PASI 75-89 (69.4% vs. 47.1%; p<. 001) and sustained DLQI 0/1 response at week 52 (74.0% vs. 56.7%; p<. 001). IGA results were similar. Conclusions: These results show that PASI 90-100 is a relevant therapeutic goal in moderate to severe psoriasis compared to PASI 75-89 when considering patients' QOL.
引用
收藏
页码:492 / 499
页数:8
相关论文
共 30 条
[1]   Assessing the overall benefit of a medication: cumulative benefit of secukinumab over time in patients with moderate-to-severe plaque psoriasis [J].
Armstrong, April W. ;
Feldman, Steven R. ;
Korman, Neil J. ;
Meng, Xiangyi ;
Guana, Adriana ;
Nyirady, Judit ;
Herrera, Vivian ;
Zhao, Yang .
JOURNAL OF DERMATOLOGICAL TREATMENT, 2017, 28 (03) :200-205
[2]   Secukinumab treatment of plaque psoriasis shows early improvement in DLQI response - results of a phase II regimen-finding trial [J].
Augustin, M. ;
Abeysinghe, S. ;
Mallya, U. ;
Qureshi, A. ;
Roskell, N. ;
McBride, D. ;
Papavassillis, C. ;
Gelfand, J. .
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2016, 30 (04) :645-649
[3]   Quality of life in psoriasis patients [J].
Augustin, Matthias ;
Radtke, Marc Alexander .
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2014, 14 (04) :559-568
[4]   Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE) [J].
Blauvelt, A. ;
Prinz, J. C. ;
Gottlieb, A. B. ;
Kingo, K. ;
Sofen, H. ;
Ruer-Mulard, M. ;
Singh, V. ;
Pathan, R. ;
Papavassilis, C. ;
Cooper, S. .
BRITISH JOURNAL OF DERMATOLOGY, 2015, 172 (02) :484-493
[5]   Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study [J].
Blauvelt, Andrew ;
Reich, Kristian ;
Tsai, Tsen-Fang ;
Tyring, Stephen ;
Vanaclocha, Francisco ;
Kingo, Kulli ;
Ziv, Michael ;
Pinter, Andreas ;
Vender, Ronald ;
Hugot, Sophie ;
You, Ruquan ;
Milutinovic, Marina ;
Thaci, Diamant .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 76 (01) :60-+
[6]   Interleukin-17 Antagonists in the Treatment of Psoriasis [J].
Chandrakumar, Shivani Felicia ;
Yeung, Jensen .
JOURNAL OF CUTANEOUS MEDICINE AND SURGERY, 2015, 19 (02) :109-114
[7]  
Christophers E., 2003, FITZPATRICKS DERMATO, V6th, P407
[8]  
deWaard-van der Spek FB, 2006, TXB PEDIAT DERMATOLO, P777
[9]   DERMATOLOGY LIFE QUALITY INDEX (DLQI) - A SIMPLE PRACTICAL MEASURE FOR ROUTINE CLINICAL USE [J].
FINLAY, AY ;
KHAN, GK .
CLINICAL AND EXPERIMENTAL DERMATOLOGY, 1994, 19 (03) :210-216
[10]   New and emerging biologic therapies for moderate-to-severe plaque psoriasis: mechanistic rationales and recent clinical data for IL-17 and IL-23 inhibitors [J].
Gaspari, Anthony A. ;
Tyring, Stephen .
DERMATOLOGIC THERAPY, 2015, 28 (04) :179-193